Table 1.
FIRE-3 | TRIBE | FIRE-3 | |||
---|---|---|---|---|---|
Treatment | FOLFIRI+Bev | FOLFIRI+Bev | FOLFIRI+Cet | ||
N | N=292 | N=210 | N=271 | P-valuea | |
Sex | 0.068 | ||||
Male | 507 | 191(65%) | 126(60%) | 190(70%) | |
Female | 266 | 101(35%) | 84(40%) | 81(30%) | |
Age | <0.001 | ||||
<65 | 421 | 144(49%) | 139(66%) | 138(51%) | |
≥65 | 352 | 148(51%) | 71(34%) | 133(49%) | |
ECOG performance status | <0.001 | ||||
0 | 473 | 160(55%) | 173(82%) | 140(52%) | |
1–2 | 299 | 132(45%) | 36(17%) | 131(48%) | |
Unspecified | 1 | - | 1(0%) | - | |
Primary tumor site | 0.13 | ||||
Right | 181 | 75(26%) | 53(25%) | 53(20%) | |
Left | 563 | 210(72%) | 142(68%) | 211(78%) | |
Unspecified | 29 | 7(2%) | 15(7%) | 7(3%) | |
Liver limited metastases | 0.87 | ||||
Yes | 250 | 95(33%) | 65(31%) | 90(33%) | |
No | 523 | 197(67%) | 145(69%) | 181(67%) | |
Number of metastatic sites | 0.39 | ||||
1 | 289 | 105(36%) | 89(42%) | 95(35%) | |
2 | 246 | 83(28%) | 85(40%) | 78(29%) | |
≥3 | 145 | 56(19%) | 36(17%) | 53(20%) | |
Unspecified | 93 | 48(16%) | - | 45(17%) | |
Primary tumor resection | <0.001 | ||||
Yes | 615 | 252(86%) | 132(63%) | 231(85%) | |
No | 157 | 40(14%) | 78(37%) | 39(14%) | |
Unspecified | 1 | - | - | 1(0%) | |
Adjuvant chemotherapy | 0.062 | ||||
Yes | 137 | 53(18%) | 27(13%) | 57(21%) | |
No | 635 | 239(82%) | 183(87%) | 213(79%) | |
Unspecified | 1 | - | - | 1(0%) | |
KRAS status | <0.001 | ||||
Wild-type | 556 | 244(84%) | 86(41%) | 226(83%) | |
Mutant | 181 | 48(16%) | 88(42%) | 45(17%) | |
Unspecified | 36 | - | 36(17%) | - | |
RAS status | <.0001 | ||||
Wild-type | 423 | 195(67%) | 49(23%) | 179(66%) | |
Mutant | 275 | 84(29%) | 110(52%) | 81(30%) | |
Unspecified | 75 | 13(4%) | 51(24%) | 11(4%) | |
BRAF status | 0.63 | ||||
Wild-type | 664 | 258(88%) | 163(78%) | 243(90%) | |
Mutant | 57 | 25(9%) | 11(5%) | 21(8%) | |
Unspecified | 52 | 9(3%) | 36(17%) | 7(3%) |
The unspecified group was not included in the analysis.
The P-value was based on the Chi-square test.